ライフサイエンスコーパス: Ph

1 Ph with mutant SAM disrupts clustering of endogenous PcG

2 Ph-like acute lymphoblastic leukemia (ALL) is a genetica

3 2) = (t)Bu, L1; R(1) = R(2) = Ph, L2; R(1) = Ph, R(2) = Naph, L3; R(1) = R(2) = Et, L4; R(1) = R(2) =

4 e organocopper complex [Cu2(mu-eta(1):eta(1)-Ph)DPFN](NTf2)2 in high yield.

5 R(1) = Naph, R(2) = (t)Bu, L1; R(1) = R(2) = Ph, L2; R(1) = Ph, R(2) = Naph, L3; R(1) = R(2) = Et, L4

6 ), HRh(P(Ph)2N(PhOMe)2)2 (8) and HRh(P(Cy)2N(Ph)2)2 (9) show that the hydrides have distorted trigona

7 , [Rh(P(Ph)2N(PhOMe)2)2](+) (3), [Rh(P(Cy)2N(Ph)2)2](+) (4), and [Rh(P(Cy)2N(PhOMe)2)2](+) (5).

8 drogen production electrocatalyst Ni(P(Ph)2N(Ph)2)2(2+) (1) is capable of traversing multiple electro

9 n synthesized and characterized: [Rh(P(Ph)2N(Ph)2)2](+) (1), [Rh(P(Ph)2N(Bn)2)2](+) (2), [Rh(P(Ph)2N(

10 ocatalytic H2 production by [Co(II)(P(tBu)2N(Ph)2)(CH3CN)3](2+) and Co(II)(dmgBF2)2(CH3CN)2.

11 26 at 0.5 muM, the ruthenium derivatives 3g (Ph) and 3d (CF3) being the best performers.

12 tion to give diazametallocyclobutene 8 (Ar=4-Ph-2,6-iPr2 C6 H2 ).

13 tion due to the trans-configuration of the 4-Ph-group and the nitrogen, but undergo 1,4-cyclization t

14 oxamic acid analogues [RCONHOH (R = PhCH2 4; Ph(CH2)2 5; Ph(CH2)3 6; Ph(CH2)4 7; Ph 8; 2-pyridyl 9; 3

15 analogues [RCONHOH (R = PhCH2 4; Ph(CH2)2 5; Ph(CH2)3 6; Ph(CH2)4 7; Ph 8; 2-pyridyl 9; 3-pyridyl 10]

16 CONHOH (R = PhCH2 4; Ph(CH2)2 5; Ph(CH2)3 6; Ph(CH2)4 7; Ph 8; 2-pyridyl 9; 3-pyridyl 10] with variou

17 PhCH2 4; Ph(CH2)2 5; Ph(CH2)3 6; Ph(CH2)4 7; Ph 8; 2-pyridyl 9; 3-pyridyl 10] with various dienes usi

18 ng it to the percentage of women receiving a Ph.D.

19 dation state +II, and tetracoordinate with a Ph group and two oxazol-2-ylidenes.

20 occur in >70% of the high-risk BCR-ABL1(+) (Ph(+)) and Ph-like disease subtypes.

21 MYB and CDK6 were highly correlated in adult Ph(+) ALL (P = 0.00008).

22 e, dexamethasone, and L-asparaginase against Ph-like ALL xenografts, offering a preclinical rationale

23 d TKI therapy is much less effective against Ph(+)B-cell acute lymphoblastic leukemia (B-ALL).

24 All Ph-like PDXs analyzed clustered within this 68-gene clas

25 Although Ph(+) ALL is defined by BCR-ABL1 fusion, Ph-like ALL cas

26 Although Ph.D. recipients spread nationally, there was also geogr

27 h mixed monolayer of phenyl and aminophenyl (Ph-PhNH2/GCE) by diazotization reaction.

28 s indicated that female representation among Ph.D. recipients is associated with the field's mathemat

29 ), platelet count (HR, 7.437; P = .005), and Ph-like ALL (HR, 1.818; P = .03).

30 ng reaction employing secondary alcohols and Ph* (Me5C6) ketones to give beta-branched carbonyl produ

31 bination of CH3OH and CD3OH or Ph-CC-CH3 and Ph-CC-CD3.

32 e high-risk early T-cell precursor (ETP) and Ph-like ALL clustering as a distinct group.

33 for Chronic Myeloid Leukemia Evaluation and Ph(+)Acute Lymphoblastic Leukemia trial, including 231 p

34 rrangement to a eta(2)-PhI intermediate, and Ph-I oxidative addition.

35 nt with the linear arrangements Ph-B-N-N and Ph-B-C-O obtained by density functional theory computati

36 g substituents (H, Me, F, CF3, MeO, NO2, and Ph) in the R4 position of the phenyl ring of 2-phenylben

37 currently further developed in pediatric and Ph(+) r/r, as well as in minimal residual disease-positi

38 70% of the high-risk BCR-ABL1(+) (Ph(+)) and Ph-like disease subtypes.

39 e Markovnikov products, Ph(Me)C(H)SiH2Ph and Ph(Me)C(H)Bpin, and (ii) hydroboration of carbodiimides

40 0.5, 0.6 and 0.8microM were obtained for AP, Ph, and NP, respectively.

41 y used for simultaneous determination of AP, Ph, and NP in tap and river waters.

42 ytic activity toward electrooxidation of AP, Ph, and NP to three well-separated peaks in the potentia

43 ate clusters of the type B12(OCH2Ar)12 (Ar = Ph or C6F5) can undergo photo-excitation with visible li

44 o) species, Cp(P)U(NAr)2((Mes)PDI(Me)) (Ar = Ph, 2-Cp(P); Ar = p-Tol, 3-Cp(P)) and Cp*U(NPh)2((Mes)PD

45 re in agreement with the linear arrangements Ph-B-N-N and Ph-B-C-O obtained by density functional the

46 ly characterized HAIYPRH, from the M13-based Ph.D.-7 phage display library, as a propagation-related

47 e from values for SAMs of oligophenyls (beta(Ph)n = 0.28 +/- 0.03 A(-1)), and significantly lower tha

48 ansfer is revealed in the Re(I)(CO)3(py)(bpy-Ph)-perylenediimide radical anion (Re(I)-bpy-PDI(-*)) dy

49 (porphinato)Zn donor (PZn), a phenyl bridge (Ph), and a naphthalene diimide acceptor (NDI), is shown

50 s (R3P)Au-SiR'Ph2 (R = Ph, Me and R' = t-Bu, Ph).

51 ol in a group format and was administered by Ph.D. psychologists in two 90-minute sessions per week.

52 s to the intermediate, (eta(5)-C5Me5)[N(Et)C(Ph)N(Et)]Mo(Cl)(NHSiMe3) (V), and XOSiMe3 as a co-produc

53 erminal imido complex, (eta(5)-C5Me5)[N(Et)C(Ph)N(Et)]Mo(NSiMe3) (3), with a 1:2 mixture of iPrOH and

54 the Mo(IV) dichloride, (eta(5)-C5Me5)[N(Et)C(Ph)N(Et)]MoCl2 (1), and the generation of 1 equiv each o

55 (CPAM) bis(carbonyl) complex [Cp*Mo{N(iPr)C(Ph)N(iPr)}(CO)2] (Cp*=eta(5)-C5Me5) serves as a precatal

56 nd 7 are stabilized by Pt-H-->Al and Pt-NH-C(Ph) = O-->Al bridging interactions, resulting in 5- and

57 pyrene (B[a]P) and benzo[c]phenanthrene (B[c]Ph) impede replication and transcription, resulting in a

58 In contrast, (+)-trans-anti-B[c]Ph-N(6)-dA dramatically reduces transcript production in

59 anscription in vitro, and (+)-trans-anti-B[c]Ph-N(6)-dA, which is a poor substrate for NER but also b

60 s of 1-phenyl-1-X-1-silacyclohexanes C5H10Si(Ph,X) (X = F (3), Cl (4)) were studied by gas-phase elec

61 CCA/Ph(-) occurred in 58 patients (10%); the most common wer

62 We further categorized CCA/Ph(-) into those in which -Y was the only clonal abnorma

63 ies in Philadelphia chromosome-negative (CCA/Ph(-)) metaphases emerge as patients with chronic phase

64 KI therapy was similar for patients with CCA/Ph(-) and those without additional chromosomal abnormali

65 In conclusion, non -Y CCA/Ph(-) are associated with decreased survival when emergi

66 We found that patients with non -Y CCA/Ph(-) had worse failure-free survival (FFS), event-free

67 In a multivariate analysis, non -Y CCA/Ph(-) increased the risk of transformation or death when

68 bserved for the G-matched duplex vs ODN(CF3-(Ph)ImdC), while for A-mismatched duplex, only a 2-fold d

69 Purpose Philadelphia chromosome (Ph) -like acute lymphoblastic leukemia (ALL) is a high-r

70 Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-ri

71 Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referr

72 Philadelphia chromosome (Ph)-like B-cell acute lymphoblastic leukemia (Ph-like AL

73 with CD20-positive, Philadelphia chromosome (Ph)-negative ALL to receive chemotherapy with or without

74 described in adult Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic

75 linical activity in Philadelphia chromosome (Ph)-negative relapsed or refractory (r/r) acute lymphobl

76 ory, CD22-positive, Philadelphia chromosome (Ph)-positive or Ph-negative B-cell acute lymphoblastic l

77 st-line therapy for Philadelphia chromosome (Ph+)-positive chronic myelogenous leukaemia.

78 ients affected by Philadelphia-positive CML (Ph(+) CML) caused by the BCR-ABL oncogene, and in this c

79 Conclusion Ph-like ALL is a highly prevalent subtype of ALL in adul

80 ib therapy seems to be beneficial to control Ph+ leukemia resistance and the quantitative model can d

81 mplex containing Pediculus humanus corporis (Ph)PINK1 bound to ubiquitin in the 'C-terminally retract

82 peroxy)propane adducts R3PO(HOO)2CMe2 (R=Cy, Ph) were synthesized and characterized.

83 ("Al") Gilman, M.D., Ph.D., represents a sad signpost for an era spanning ove

84 in swings the aromatic rings from downstream Phes in the cavity of the channel, which blocks ion flux

85 s and chromatin interactions while elevating Ph level increases cluster number and chromatin interact

86 ith 1-OSiMe3 to eliminate the disilyl ethers Ph(n)H(3-n)SiOSiMe3 (n = 1 or 2) and generate the nickel

87 The CF3 analogue participates in fast Ph-CF3 coupling (<5 min at 80 degrees C).

88 derivative (OEP)Fe(PhNO)(5-MeIm) and (OEP)Fe(Ph).

89 d Suzuki-Miyaura reactions indicates that Fe(Ph)X(SciOPP) (X = Br, Cl) is the predominant reactive sp

90 oup on Adult ALL (EWALL) study number 01 for Ph(+) ALL (EWALL-PH-01 international study) and were tre

91 -medicine testing and treatment approach for Ph-like ALL implemented in Children's Oncology Group ALL

92 val and overall survival were determined for Ph-like ALL versus non-Ph-like ALL patients.

93 elations show that substituting hydrogen for Ph-I(+) at the carbanionic center of Meldrum's acid or d

94 t SCT in first CR is still a good option for Ph+ ALL adult patients.

95 onse to imatinib, the standard treatment for Ph(+) CML.

96 tions, suggests a d(10) configuration for [((Ph) DPB(iPr) )Ni(H2 )] as most appropriate.

97 s), endowed with antileukemia activity, from Ph(+) ALL patients and healthy donors.

98 ugh Ph(+) ALL is defined by BCR-ABL1 fusion, Ph-like ALL cases contain a variety of genomic alteratio

99 o study the immunosensing performance of GNS/Ph-PhNH2/GCE, first the capturing antibody (rabbit-anti

100 ovalently attached on electrode surface (GNS/Ph-PhNH2/GCE).

101 ng R group [CH3 --> Ph --> Naph --> Anth --> Ph(OMe)2] improves both the band-edge position and Delta

102 dulation of the passivating R group [CH3 --> Ph --> Naph --> Anth --> Ph(OMe)2] improves both the ban

103 sm(Pr(i)Benz)]MgX [X = F, Cl, Br, I, SH, N(H)Ph, CH(Me)Ph, O2CMe, S2CMe].

104 ane monomers R(1)R(2)P-BH2NMe3 (R(1),R(2)=H, Ph, or tBu/H) at room temperature to 100 degrees C provi

105 (N2(iPr)N)(NNPh2)(py) with Ph(R)SiH2 (R = H, Ph) or 9-BBN gave reductive cleavage of the N(alpha)-N(b

106 constant for cyclization below that of the H/Ph-substituted 2e, 2f.

107 f 148 patients, 33.1% had Ph-like, 31.1% had Ph(+), and 35.8% had other B-ALL subtypes (B-other).

108 Of 148 patients, 33.1% had Ph-like, 31.1% had Ph(+), and 35.8% had other B-ALL subt

109 with length-matched SAMs of oligophenyls (HS(Ph)nH) and n-alkanethiols (HS(CH2)nH) demonstrates that

110 ed similar gene expression profiles to human Ph-like B-ALLs, supporting use of this model for preclin

111 urther reinforced by Topliss in 1972 that if Ph was active, the p-ClPh should be made because of ease

112 mplexes of general structure (P(t)Bu3)Pd(II)(Ph)(RF).

113 II (PSII)-inspired [Ru(bpy)2(phen-imidazole-Ph(OH)((t)Bu)2)](2+), in which Ru(III) generated by a fl

114 on and cytogenetic abnormalities, and (2) in Ph(+) CML, it synergizes with BCR-ABL signaling, reducin

115 Cytotoxicity was consistently most acute in Ph-like BCP-ALL.

116 Additional genomic alterations in Ph-like ALL activate other kinases, including BLNK, DGKH

117 se range of kinase-activating alterations in Ph-like ALL has important therapeutic implications.

118 otherapeutic approaches with BCR-ABL CTLs in Ph(+) ALL.

119 were consistent with previous experience in Ph(-) ALL.

120 otein LNK (also known as SH2B3) are found in Ph-like ALLs; however, it is not clear how LNK regulates

121 of brilliance do not predict gender gaps in Ph.D. attainment beyond mathematics and verbal test scor

122 duced-intensity chemotherapy and imatinib in Ph+ ALL adult patients and suggests that SCT in first CR

123 testing combinations of kinase inhibitors in Ph-like ALL patients are indicated.

124 hibitors have been minimally investigated in Ph-like ALL.

125 ling was predictive of treatment outcomes in Ph(+) leukemia patients.

126 enes previously reported to be rearranged in Ph-like ALL.

127 Consistent with their essential role in Ph(+) ALL, pharmacologic inhibition of CDK6 and BCL2 mar

128 2 represent promising targets for therapy in Ph(+)hematologic neoplasms.

129 G protein Polyhomeotic (Ph) or by increasing Ph levels.

130 roethanol than the parent benzhydrylium ion (Ph)2CH(+), even though in solvolysis reactions (80% aque

131 Nonsubstituted phenyl nitrenium ions (Ph-NH(+)) and phenyl oxenium ions (Ph-O(+)) have closed-

132 ium ions (Ph-NH(+)) and phenyl oxenium ions (Ph-O(+)) have closed-shell singlet ground states with la

133 kinetic stereoselectivity to produce isomer Ph(Cl)Si(ON[Me]O) in which the phenyl is axial in the tr

134 osome-positive acute lymphoblastic leukemia (Ph(+) ALL) is currently treated with BCR-ABL1 tyrosine k

135 osome-positive acute lymphoblastic leukemia (Ph(+) ALL) undergoing maintenance tyrosine-kinase inhibi

136 osome-positive acute lymphoblastic leukemia (Ph+ ALL) is initiated and driven by the oncogenic fusion

137 hromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk ALL commonly associated with

138 h)-like B-cell acute lymphoblastic leukemia (Ph-like ALL) is associated with activated JAK/STAT, Abel

139 hromosome-like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profi

140 osome-negative acute lymphoblastic leukemia (Ph-neg ALL) do not appear to require an allogeneic stem

141 Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-ri

142 r gene EPOR in Philadelphia chromosome-like (Ph-like) ALL.

143 hinoalkylidene (PNP)Ti horizontal lineCHPPh2(Ph) (1).

144 oxo atom donor adduct, Fe-O horizontal lineI-Ph, or an Fe(V) horizontal lineO remains to be determine

145 clopropyl ketone > t-Bu-C( horizontal lineO)-Ph > diisopropyl ketone >> t-Bu2C horizontal lineO > ClS

146 nz)]MgX [X = F, Cl, Br, I, SH, N(H)Ph, CH(Me)Ph, O2CMe, S2CMe].

147 ide (RC)-Ph2P( horizontal lineNCO2Me)NHCH(Me)Ph (5; dr of 95:5) with tert-butyllithium in THF has bee

148 mplexes [PhBP3]RuH(eta(3)-H2SiRR') (RR' = Me,Ph, 1a; RR' = Ph2, 1b; RR' = Et2, 1c) react with XylNC t

149 mplexes Pt(SnR3)2(CNBu(t))2 (R = Bu(t), Mes, Ph, or Pr(i)), only the Bu(t) analogue does both H2 acti

150 In a chronic renal failure model, Phd(2/3)hKO mice maintained normal hematocrit levels thr

151 Moreover, Ph(+) ALL cells exhibited a specific requirement for CDK

152 (C5Me5)2Y(mu-Ph)2BPh2, 1, reacted with ethyllithium at -15 degrees C

153 turated dirhenium complex [Re2(CO)8(mu-H)(mu-Ph)] (1) has been found to exhibit aromatic C-H activati

154 My Ph.D. thesis in the laboratory of Severo Ochoa at New Yo

155 degrees from the University of Hawaii and my Ph.D. from the University of California at Davis.

156 ate shows that compared to N-Me, N-iPr and N-Ph variants, the N-o-tolyl variant of the rhodium enolat

157 y reacting Au144(SCH2CH2Ph)60 with HS-(CH2)n-Ph (where n = 1 and 2), bulky ligands like adamantanethi

158 h))2(CH2CN)][BF4]2 in acetonitrile (P2(Ph)N2(Ph) = 1,3,5,7-tetraphenyl-1,5-diaza-3,7-diphosphacyclooc

159 the hydrogen evolution catalyst [Ni(P2(Ph)N2(Ph))2(CH2CN)][BF4]2 in acetonitrile (P2(Ph)N2(Ph) = 1,3,

160 y dissociation PhCN from (BINAP)Ni(eta(2)-NC-Ph), but the aryl bromide directly reacts with (BINAP)Ni

161 ide directly reacts with (BINAP)Ni(eta(2)-NC-Ph).

162 t benzene produces diamagnetic complex 3 [Ni(Ph)(PN(P)N(H))], which is crystallographically character

163 tions, 4a,b are faster catalysts than the Ni(Ph)(PPh3) analogue, a previously reported benchmark.

164 as the utility of targeted therapies in non-Ph-positive MPALs is unknown.

165 l were determined for Ph-like ALL versus non-Ph-like ALL patients.

166 ree survival compared with patients with non-Ph-like ALL (22.5% [95% CI, 14.9% to 29.3%; n = 155] v 4

167 al strategy to target the MYB "addiction" of Ph(+) ALL.Significance: MYB blockade can suppress Philad

168 ike ALL in adults, an increased frequency of Ph-like ALL in adults of Hispanic ethnicity, significant

169 Our findings show high frequency of Ph-like ALL in adults, an increased frequency of Ph-like

170 Patients and Methods The frequency of Ph-like ALL was assessed by gene expression profiling of

171 We show here that (i) the growth of Ph(+) ALL cell lines and primary cells is highly depende

172 ve helped to define the genomic landscape of Ph-like ALL and how it varies across the age spectrum, a

173 fine the prevalence and genomic landscape of Ph-like ALL in adults and assess response to conventiona

174 ance selection approach in a murine model of Ph(+) acute lymphoblastic leukemia, we indeed find that

175 Using a mouse model of Ph+ ALL that accurately mimics the genetics, clinical be

176 erial composition between two populations of Ph. chinensis from Henan and Sichuan, China.

177 cting data on the incidence and prognosis of Ph-like ALL in adults.

178 Loss of Cg leads to decreased recruitment of Ph at only a subset of sites; some of these sites are bi

179 This Communication describes studies of Ph-RF (RF = CF3 or CF2CF3) coupling at Pd complexes of g

180 tly worse outcomes in the CRLF2(+) subset of Ph-like ALL.

181 iferation, colony formation, and survival of Ph(+) ALL cells ex vivo and in mice.

182 that shares significant overlap with that of Ph-positive (Ph(+)) ALL and is suggestive of activated k

183 utility of these agents in the treatment of Ph-like ALL.

184 ons suggested that the dominant tautomer of (Ph)ImC in methanol solution is identical to that of cyti

185 by using a combination of CH3OH and CD3OH or Ph-CC-CH3 and Ph-CC-CD3.

186 nal diagnoses were made by a blinded M.D. or Ph.D. evaluator.

187 de (PI) oligomers (Xn-R, n = 2-4, R = Hex or Ph) linked together by single C-C bonds between their be

188 2,5-dimethylpyrrolyl (Me2Pyr) and R = Me or Ph) was prepared by grafting bis-X substituted complexes

189 ions of Cp*Ti{MeC(N(i)Pr)2}(NNR2) (R = Me or Ph) with HBPin or 9-BBN gave borylhydrazido-hydride or b

190 ve, Philadelphia chromosome (Ph)-positive or Ph-negative B-cell acute lymphoblastic leukaemia who wer

191 e synthesis and characterization of new P2(P'Ph) Fe(N2 )(H)x systems that are active for catalytic N2

192 ized, and X-ray diffraction studies of HRh(P(Ph)2N(Bn)2)2 (7), HRh(P(Ph)2N(PhOMe)2)2 (8) and HRh(P(Cy

193 ion studies of HRh(P(Ph)2N(Bn)2)2 (7), HRh(P(Ph)2N(PhOMe)2)2 (8) and HRh(P(Cy)2N(Ph)2)2 (9) show that

194 al dynamics on H2 production rates for [Ni(P(Ph)2 N(C6H4R)2 )2 ](2+) catalysts (R=n-hexyl, n-decyl, n

195 The hydrogen production electrocatalyst Ni(P(Ph)2N(Ph)2)2(2+) (1) is capable of traversing multiple e

196 acterized: [Rh(P(Ph)2N(Ph)2)2](+) (1), [Rh(P(Ph)2N(Bn)2)2](+) (2), [Rh(P(Ph)2N(PhOMe)2)2](+) (3), [Rh

197 ve been synthesized and characterized: [Rh(P(Ph)2N(Ph)2)2](+) (1), [Rh(P(Ph)2N(Bn)2)2](+) (2), [Rh(P(

198 2](+) (1), [Rh(P(Ph)2N(Bn)2)2](+) (2), [Rh(P(Ph)2N(PhOMe)2)2](+) (3), [Rh(P(Cy)2N(Ph)2)2](+) (4), and

199 h)N2(Ph))2(CH2CN)][BF4]2 in acetonitrile (P2(Ph)N2(Ph) = 1,3,5,7-tetraphenyl-1,5-diaza-3,7-diphosphac

200 d for the hydrogen evolution catalyst [Ni(P2(Ph)N2(Ph))2(CH2CN)][BF4]2 in acetonitrile (P2(Ph)N2(Ph)

201 (3)-H2SiRR') (RR' = MePh, 1a; Ph2, 1b; [PhBP(Ph)3](-) = [PhB(CH2PPh2)3](-)) are efficient catalysts (

202 ophilic eta(3)-H2SiRR' sigma-complexes [PhBP(Ph)3]RuH(eta(3)-H2SiRR') (RR' = MePh, 1a; Ph2, 1b; [PhBP

203 H3CH2, CH3CH2CH2, (CH3)2CH, PhCH2CH2, PhCH2, Ph, C3H5, and H) were reacted with CH3I.

204 etermination of 4-Amino Phenol (AP), Phenol (Ph) and 4-Nitro Phenol (NP).

205 yl (MeOMe), R = methyl (Me), and R = phenyl (Ph)] were found in German rivers and streams.

206 alculations to substituted phenylacetylenes (Ph-C identical withC-Y) predicts a similar reactivity of

207 In the case of phenylmethoxyacetylene (Ph-C identical withC-OCH3) the good yield of the corresp

208 eaction is investigated for 1-phenylpropyne (Ph-CC-CH3) using [AuCl(PPh3)]/AgSbF6 and [AuCl(IPr)]/AgS

209 -risk ALL (HR-ALL) without the Philadelphia (Ph) chromosome to chemotherapy or to allogeneic hematopo

210 t BCR-ABL1, the product of the Philadelphia (Ph) chromosome, have revolutionized treatment of patient

211 2-phenyl-1H-phenanthro[9,10-d]imidazole (PI-Ph), was synthesized and investigated in comparison with

212 kyl, aryl; R'=H, alkyl, aryl), and pinBSiMe2 Ph.

213 e all-ferrous species ([(tren) L)2 Fe8 (PMe2 Ph)2 ] (1) displays a bicapped octahedral geometry with

214 duced clusters [M](+) [((tren) L)2 Fe8 (PMe2 Ph)2 ](-) (M=Bu4 N (2 a); (15-crown-5)Na(thf) (2 b)) wer

215 oteins Pleiohomeotic (Pho) and Polyhomeotic (Ph) at the majority of PREs in the genome.

216 motif (SAM) of the PcG protein Polyhomeotic (Ph) or by increasing Ph levels.

217 th CML and Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukaemia.

218 e (CMR) in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) remains undefi

219 ients with Philadelphia chromosome-positive (Ph(+)) B-precursor acute lymphoblastic leukemia (ALL) wh

220 e model of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) by combined targ

221 Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is characterized

222 ears) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

223 diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

224 y stage of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).

225 ignificant overlap with that of Ph-positive (Ph(+)) ALL and is suggestive of activated kinase signali

226 ients have functional Philadelphia positive (Ph+) stem and progenitor cells in their bone marrows and

227 Prognosis of Philadelphia-positive (Ph(+)) acute lymphoblastic leukemia (ALL) in the elderly

228 tcome for younger adults with CD20-positive, Ph-negative ALL.

229 styrene to afford the Markovnikov products, Ph(Me)C(H)SiH2Ph and Ph(Me)C(H)Bpin, and (ii) hydroborat

230 vImJ, A/J, C57BL/6J, DBA/1J, DBA/2J, and PWD/Ph) to provide a perspective on differences between male

231 o metal hydride complexes, (eta(5)-C5Me5)(py-Ph)Rh-H (py-Ph = 2-pyridylphenyl, [Rh]-H) and (eta(5)-C5

232 The rhodium hydride, (eta(5)-C5Me5)(py-Ph)RhH (py-Ph = 2-phenylpyridine), serves as the catalys

233 ide complexes, (eta(5)-C5Me5)(py-Ph)Rh-H (py-Ph = 2-pyridylphenyl, [Rh]-H) and (eta(5)-C5R5)(CO)3Cr-H

234 hodium hydride, (eta(5)-C5Me5)(py-Ph)RhH (py-Ph = 2-phenylpyridine), serves as the catalyst and promo

235 novo designed a protein SCPZnI3 to bind PZn-Ph-NDI in its interior.

236 We calibrated PZn-Ph-NDI ET dynamics as a function of solvent dielectric,

237 A linked donor-bridge-acceptor molecule, PZn-Ph-NDI, consisting of a (porphinato)Zn donor (PZn), a ph

238 PH with 3 yield 3-(R2PH)C16H7O2B(C6F5)2 (R = Ph (9), t-Bu (10)).

239 le 1-Cp* and 1-Cp(P) readily reduce N3R (R = Ph, p-tolyl) to form trans-bis(imido) species, Cp(P)U(NA

240 u-Si bonds of complexes (R3P)Au-SiR'Ph2 (R = Ph, Me and R' = t-Bu, Ph).

241 )Cl( horizontal lineCHPh)(IPr)(P(i)Pr3) (R = Ph (6), CO2Me (7)) as a consequence of the migration of

242 OR ethers was observed to range from 50 % (R=Ph) to greater than 90 % (R=n-C4 H9 , cyclohexyl, and Ph

243 NHR')][BAr(F) 4 ] (L(R) =R2 P(CH2 )3 PR2 ; R=Ph, (i) Pr; R'=H, Me) form by addition of H3 BNMeR'H2 to

244 Addition of PR3 (R=Ph or OPh) to [Cu(eta(2)-Me6C6)2][PF6] results in the fo

245 Our data suggest that Cg can recruit Ph in the absence of PRC1 and illustrate the diversity a

246 omab in patients with relapsed or refractory Ph(+) ALL.

247 capable of controlling treatment-refractory Ph(+) ALL in vivo, and support the development of adopti

248 ped an in vitro model of Nilotinib-resistant Ph+ leukemia cells to investigate whether low dose radia

249 action paths reveal that the two aryl rings (Ph vs PhNMe2) do not interact in a dynamic manner as the

250 some humanities (e.g., in 2011, 54% of U.S. Ph.D.'s in molecular biology were women versus only 31%

251 nyl group by a larger polarization of the Si-Ph than of the Si-O bond in the Phax conformer and addit

252 ) restoring their expression in MYB-silenced Ph(+) ALL cells rescues their impaired proliferation and

253 ex [Ru(=C=CHF)(eta(5) -C5 Me5 )(dppe)][N(SO2 Ph)2 ].

254 ex [Ru(C=CF2 )(eta(5) -C5 Me5 )(dppe)][N(SO2 Ph)2 ].

255 nt signaling pathways are active in specific Ph-like ALL subsets, and precision medicine trials have

256 l that the flat-band potential of the stable Ph(OMe)2 surface approaches that of the native (but unst

257 feature of the reaction is that the stronger Ph-O bond is cleaved rather than the weaker aliphatic O-

258 Newly developed TKI can target Ph(+) ALL cells with BCR-ABL1-dependent resistance; howe

259 owly (half-lives 1.15 yrs and 33 days) than (Ph)2CH-Br (half-life 23 s).

260 Here we show that Phd also functions as a chaperone, keeping Doc in an act

261 The Ph-like gene expression profile was identified in 341 of

262 reactive toward PhI as 3 itself; and 2) the Ph-I bond cleavage with the just-produced 2 gives rise t

263 However, women are well represented at the Ph.D. level in some sciences and poorly represented in s

264 of styrene, Ph3P (3), and N2 (4)) cleave the Ph-X bond (X = Cl, Br, I) at RT to give [(Ph3P)3RuH(X)]

265 bout the Si-CPh bond (axi and axo denote the Ph group lying in or out of the X-Si-CPh plane) contribu

266 ies generated, serving as a catalyst for the Ph-CF3 bond formation even if 1 is used in stoichiometri

267 es through extra interaction with one of the Ph substituents.

268 While Fc undergoes one, the Ph-based apFr depends on temperature.

269 By utilizing the Ph* group, the beta-branched products could be straightf

270 pration in the presence of an imine with the Ph-BPE-derived copper catalyst.

271 Within the Ph-like ALL cohort, 61% had cytokine receptor-like facto

272 mall, abundant clusters on chromatin through Ph SAM polymerization activity may shape genome architec

273 Upon binding to Phd, Doc becomes more compact and is secured in its mono

274 reactivities of 1-OSiMe3 and 2-OSiMe3 toward Ph(n)SiH(4-n) (dimerization, polymerization, and redistr

275 netic abnormality (chromosomal translocation Ph(+): t(9;22)(q34;q11)) at the stem cell level causes i

276 n identified in literature reports that used Ph.D.-7 library.

277 t-derived xenograft models harboring various Ph-like genomic alterations with 4 discrete PI3K pathway

278 = cyclohexyl) and Au28(SPh-(t)Bu)20 (where -Ph-(t)Bu = 4-tert-butylphenyl).

279 en-label phase II study enrolled adults with Ph(+) ALL who had relapsed after or were refractory to a

280 In addition, Cg colocalizes with Ph at a number of targets independent of Pho.

281 Patients with Ph(+) ALL who achieve CMR at 3 months have superior surv

282 leukemia activity in high-risk patients with Ph(+) ALL who had relapsed or were refractory to TKIs.

283 ct of CMR on outcomes among 85 patients with Ph(+) ALL who received first-line hyperfractionated cycl

284 We treated 3 patients with Ph(+) ALL with autologous or allogeneic (p190)BCR-ABL-sp

285 erm survival in 36% of elderly patients with Ph(+) ALL.

286 Results Patients with Ph-like ALL accounted for more than 20% of adults with A

287 Overall, patients with Ph-like ALL had an inferior 5-year event-free survival c

288 Patients with Ph-like ALL had significantly worse overall survival (OS

289 Sixty-eight percent of patients with Ph-like ALL were of Hispanic ethnicity.

290 tly inferior outcomes of adult patients with Ph-like ALL, and significantly worse outcomes in the CRL

291 tivating alterations in 88% of patients with Ph-like ALL, including CRLF2 rearrangements (51%), ABL c

292 is was performed on 180 of 194 patients with Ph-like ALL.

293 tailed genomic analysis of 154 patients with Ph-like ALL.

294 in a large series of 617 adult patients with Ph-negative BCP-ALL (median age, 38 years), treated in t

295 Reaction of Ti(N2(iPr)N)(NNPh2)(py) with Ph(R)SiH2 (R = H, Ph) or 9-BBN gave reductive cleavage o

296 KRAS, NRAS, NF1, PTPN11) in 6% of those with Ph-like ALL.

297 X-ray crystallography shows that X2-Ph crystallizes into a densely packed superstructure, de

298 -dimethylxanthene) precatalysts [Ru(Xantphos(Ph))(PhCO2)(Cl)] (1) and [Ru(Xantphos(Cy))(PhCO2)(Cl)] (

299 computations using novel ruthenium Xantphos(Ph) (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene) an

300 ctivation toward CumO(*) is observed for Z = Ph, OH, NH2, and NHAc, as evidenced by an increase in kH